{{Rsnum
|rsid=7086128
|Chromosome=10
|position=126587373
|Orientation=plus
|GMAF=0.1777
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 69.0 | 29.2 | 1.8
| HCB | 64.7 | 32.4 | 2.9
| JPT | 57.5 | 37.2 | 5.3
| YRI | 59.2 | 34.7 | 6.1
| ASW | 64.9 | 28.1 | 7.0
| CHB | 64.7 | 32.4 | 2.9
| CHD | 70.6 | 24.8 | 4.6
| GIH | 70.0 | 24.0 | 6.0
| LWK | 64.5 | 32.7 | 2.7
| MEX | 63.2 | 31.6 | 5.3
| MKK | 52.3 | 41.9 | 5.8
| TSI | 75.5 | 22.5 | 2.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs7086128
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: G, MAF= 0.15, combined P value= 1.30E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470194
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs7086128
|overall_frequency_n=21
|overall_frequency_d=126
|overall_frequency=0.166667
|n_genomes=20
|n_genomes_annotated=0
|n_haplomes=21
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}